Advertisement

Drug-Coated Balloons: Lessons from the Real World

  • Damiano Regazzoli
  • Marco Bruno Ancona
  • Pier Pasquale Leone
  • Azeem Latib
Chapter

Abstract

Drug-coated balloons (DCBs) offer a non-stent-based antiproliferative drug delivery system to treat coronary lesions. Over the years they were validated in several settings and widely used both in clinical trials and in daily practice. The aim of this chapter is to evaluate the clinical performance and rationale of DCB use in “real-world” scenarios in coronary artery disease.

References

  1. 1.
    Basavarajaiah S, Latib A, Shannon J, et al. Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery disease: real-world experience from our registry. J Interv Cardiol. 2014;27:348–55.CrossRefGoogle Scholar
  2. 2.
    Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113–24.CrossRefGoogle Scholar
  3. 3.
    Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (balloon elution and late loss optimization) study. J Am Coll Cardiol. 2012;60:2473–80.CrossRefGoogle Scholar
  4. 4.
    Latib A, Ruparelia N, Menozzi A, et al. 3-year follow-up of the balloon elution and late loss optimization study (BELLO). JACC Cardiovasc Interv. 2015;8:1132–4.CrossRefGoogle Scholar
  5. 5.
    Sinaga DA, Ho HH, Watson TJ, et al. Drug-coated balloons: a safe and effective alternative to drug-eluting stents in small vessel coronary artery disease. J Interv Cardiol. 2016;29:454–60.CrossRefGoogle Scholar
  6. 6.
    Tanaka A, Latib A, Jabbour RJ, et al. Impact of angiographic result after Predilatation on outcome after drug-coated balloon treatment of in-stent coronary restenosis. Am J Cardiol. 2016;118:1460–5.CrossRefGoogle Scholar
  7. 7.
    Picard F, Doucet S, Asgar AW. Contemporary use of drug-coated balloons in coronary artery disease: where are we now? Arch Cardiovasc Dis. 2017;110(4):259–72.CrossRefGoogle Scholar
  8. 8.
    Cowley MJ, Dorros G, Kelsey SF, et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol. 1984;53:12C–6C.CrossRefGoogle Scholar
  9. 9.
    Cappelletti A, Margonato A, Rosano G, et al. Short- and long-term evolution of unstented nonocclusive coronary dissection after coronary angioplasty. J Am Coll Cardiol. 1999;34:1484–8.CrossRefGoogle Scholar
  10. 10.
    Tepe G, Zeller T, Schnorr B, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.CrossRefGoogle Scholar
  11. 11.
    Chan YH, Agostoni P. SEDUCEd by optical coherence tomography in drug-eluting balloon assessment. EuroIntervention. 2014;10:415–7.CrossRefGoogle Scholar
  12. 12.
    Agostoni P, Belkacemi A, Voskuil M, et al. Serial morphological and functional assessment of drug- eluting balloon for in-stent restenotic lesions mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. JACC Cardiovasc Interv. 2013;6:569–76.CrossRefGoogle Scholar
  13. 13.
    Cortese B, Silva Orrego P, Agostoni P, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv. 2015;8(15):2003–9.CrossRefGoogle Scholar
  14. 14.
    Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–5.CrossRefGoogle Scholar
  15. 15.
    Pires NM, Eefting D, de Vries MR, et al. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart. 2007;93:922–7.CrossRefGoogle Scholar
  16. 16.
    Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004;25:1330–40.CrossRefGoogle Scholar
  17. 17.
    Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5:392–400.CrossRefGoogle Scholar
  18. 18.
    Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636–45.CrossRefGoogle Scholar
  19. 19.
    Kleber FX, Schulz A, Waliszewski M, et al. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015;104(3):217–25.CrossRefGoogle Scholar
  20. 20.
    Kakuta T, Currier JW, Haudenschild CC, et al. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809–15.CrossRefGoogle Scholar
  21. 21.
    Godino C, Furuichi S, Latib A, et al. Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE registry). Am J Cardiol. 2008;102:1002–8.CrossRefGoogle Scholar
  22. 22.
    Mehilli J. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2005;27:260–6.CrossRefGoogle Scholar
  23. 23.
    Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969–76.CrossRefGoogle Scholar
  24. 24.
    Scheller B. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810–4.CrossRefGoogle Scholar
  25. 25.
    Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010;96:1291–6.CrossRefGoogle Scholar
  26. 26.
    Fröhlich GM, Lansky AJ, Ko DT, et al. Drug eluting balloons for de novo coronary lesions—a systematic review and meta-analysis. BMC Med. 2013;11:123.CrossRefGoogle Scholar
  27. 27.
    Giannini F, Latib A, Ancona MB, et al. Propensity score matched comparative study between paclitaxel-coated balloon and Everolimus-eluting stents for the treatment of small coronary vessels. Catheter Cardiovasc Interv. 2017;90(3):380–6.CrossRefGoogle Scholar
  28. 28.
    Giannini F, Latib A, Jabbour RJ, et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients—results from the BELLO (balloon elution and late loss optimization) trial. Cardiovasc Revasc Med. 2017;18(1):4–9.CrossRefGoogle Scholar
  29. 29.
    Basavarajaiah S, Latib A, Hasegawa T, et al. Assessment of efficacy and safety of combining “paclitaxel” eluting balloon and “limus” eluting stent in the same lesion. J Interv Cardiol. 2013;26(3):259–63.CrossRefGoogle Scholar
  30. 30.
    de Ribamar Costa J Jr, Mintz GS, Carlier SG, Fujii K, et al. Intra-vascular ultrasound assessment of drug-eluting stent expansion. Am Heart J. 2007;153:297–303.CrossRefGoogle Scholar
  31. 31.
    Moussa I, Moses J, Di Mario C, et al. Stenting after optimal lesion debulking (sold) registry. Angiographic and clinical outcome. Circulation. 1998;98:1604–9.CrossRefGoogle Scholar
  32. 32.
    Lee CW, Park DW, Lee BK, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol. 2006;97:506–11.CrossRefGoogle Scholar
  33. 33.
    D’Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167:575–84.CrossRefGoogle Scholar
  34. 34.
    Sharp AS, Latib A, Ielasi A, et al. Long-term follow-up on a large cohort of “full-metal jacket” percutaneous coronary intervention procedures. Circ Cardiovasc Interv. 2009;2:416–22.CrossRefGoogle Scholar
  35. 35.
    Costopoulos C, Latib A, Naganuma T, et al. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease. JACC Cardiovasc Interv. 2013;6(11):1153–9.CrossRefGoogle Scholar
  36. 36.
    Colombo A, Latib A. Can long-term results following balloon angioplasty be the “crystal ball” to predict outcome following bioresorbable vascular scaffolds? J Am Heart Assoc. 2012;1:e005272.CrossRefGoogle Scholar
  37. 37.
    Tamburino C, Capranzano P, Gori T, et al. 1-year outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: a propensity-matched comparison of the GHOST-EU and XIENCE V USA registries. JACC Cardiovasc Interv. 2016;9:440–9.CrossRefGoogle Scholar
  38. 38.
    Tanaka A, Latib A, Kawamoto H, et al. Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy. EuroIntervention. 2017;12:1730–7.CrossRefGoogle Scholar
  39. 39.
    Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899–907.CrossRefGoogle Scholar
  40. 40.
    Tanaka A, Jabbour RJ, Mitomo S, et al. Hybrid percutaneous coronary intervention with Bioresorbable vascular scaffolds in combination with drug-eluting stents or drug-coated balloons for complex coronary lesions. JACC Cardiovasc Interv. 2017;10:539–47.CrossRefGoogle Scholar
  41. 41.
    Kawamoto H, Jabbour RJ, Tanaka A, et al. Contained coronary rupture following bioresorbable scaffold implantation in a small vessel. Int J Cardiol. 2016;209:24–5.CrossRefGoogle Scholar
  42. 42.
    Jamshidi P, Nyffenegger T, Sabti Z, et al. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention. 2016;11:1479–86.CrossRefGoogle Scholar
  43. 43.
    Ielasi A, Miyazaki T, Geraci S, et al. Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the “no more metallic cages” multicentre pilot experience. EuroIntervention. 2016;11:e1589–95.CrossRefGoogle Scholar
  44. 44.
    Toyofuku M, Kimura T, Morimoto T, et al. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry. JACC Cardiovasc Interv. 2013;6:654–63.CrossRefGoogle Scholar
  45. 45.
    Toyofuku M, Kimura T, Morimoto T, et al. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. Circulation. 2009;120:1866–74.CrossRefGoogle Scholar
  46. 46.
    Palmerini T, Marzocchi A, Tamburino C, et al. Impact of bifurcation technique on 2-year clinical outcomes in 773 patients with distal unprotected left main coronary artery stenosis treated with drug-eluting stents. Circ Cardiovasc Interv. 2008;1:185–92.CrossRefGoogle Scholar
  47. 47.
    Takagi K, Naganuma T, Chieffo A, et al. Comparison between 1- and 2-stent strategies in unprotected distal left main disease: the Milan and New-Tokyo registry. Circ Cardiovasc Interv. 2016;9:e003359.CrossRefGoogle Scholar
  48. 48.
    Cortese B, Piraino D, Buccheri D, Alfonso F. Treatment of bifurcation lesions with drug-coated balloons: a review of currently available scientific data. Int J Cardiol. 2016;220:589–94.CrossRefGoogle Scholar
  49. 49.
    Piraino D, Cortese B, Buccheri D, Dendramis G, Andolina G. Healing after coronary artery dissection: the effect of a drug coated balloon angioplasty in a bifurcation lesion. A lesson from intravascular ultrasound analysis. Int J Cardiol. 2016;203:298–300.CrossRefGoogle Scholar
  50. 50.
    Jackson D, Tong D, Layland J. A review of the coronary applications of the drug coated balloon. Int J Cardiol. 2017;226:77–86.CrossRefGoogle Scholar
  51. 51.
    Stella PR, Belkacemi A, Dubois C, et al. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare- metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv. 2012;80:1138–46.CrossRefGoogle Scholar
  52. 52.
    Alfonso F, Perez-Vizcayno MJ, Cardenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V clinical trial (restenosis intra-stent of bare metal stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63:1378–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Damiano Regazzoli
    • 1
  • Marco Bruno Ancona
    • 1
  • Pier Pasquale Leone
    • 1
  • Azeem Latib
    • 1
  1. 1.Unit of Cardiovascular InterventionsIRCCS San Raffaele Scientific Institute, San Raffaele University HospitalMilanItaly

Personalised recommendations